Post-transplant lymphoproliferative disorder - Revision history

Michael: /* IHC */

2019-12-26T19:56:42Z

IHC

← Older revision		Revision as of 19:56, 26 December 2019
Line 18:		Line 18:
	==IHC==		==IHC==
	*B cell markers +ve.		*B cell markers +ve.
	*EBER diffusely +ve.		*[[EBER]] diffusely +ve.

	==See also==		==See also==

Michael: /* See also */

2017-03-24T17:37:09Z

Michael: /* References */ +cat.

2011-10-18T02:05:19Z

References: +cat.

← Older revision		Revision as of 02:05, 18 October 2011
Line 26:		Line 26:

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|2}}

	[[Category:Haematopathology]]		[[Category:Haematopathology]]
			[[Category:Diagnosis]]

Michael: fix typo

2011-05-04T14:23:07Z

fix typo

← Older revision		Revision as of 14:23, 4 May 2011
Line 1:		Line 1:
	'''Post-transplant lymphoproliferative disorder''', ~~vbbreviated~~ ''PTLD'', is something afflicts people that had transplants (solid organ and bone marrow). It is essentially a type of B-cell [[lymphoma]].		'''Post-transplant lymphoproliferative disorder''', abbreviated ''PTLD'', is something afflicts people that had transplants (solid organ and bone marrow). It is essentially a type of B-cell [[lymphoma]].

	==General==		==General==

Michael: wikify

2011-04-14T15:03:08Z

wikify

← Older revision		Revision as of 15:03, 14 April 2011
Line 3:		Line 3:
	==General==		==General==
	*Rare.		*Rare.
	*B cell neoplasm associated with EBV.<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>		*B cell neoplasm associated with [[EBV]].<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>
	**May develop from a clinically latent EBV infection that is detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/]. Accessed on: 3 March 2011.</ref>		**May develop from a clinically latent EBV infection that is detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/]. Accessed on: 3 March 2011.</ref>
	*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.		*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.

Michael at 15:51, 3 March 2011

2011-03-03T15:51:08Z

← Older revision		Revision as of 15:51, 3 March 2011
Line 12:		Line 12:
	**Large lymphoid cells with a diameter ~2x a resting lymphocyte.		**Large lymphoid cells with a diameter ~2x a resting lymphocyte.
	**Nucleoli.		**Nucleoli.

			DDx:
			*[[Diffuse large B cell lymphoma]].

	==IHC==		==IHC==
	*B cell markers +ve		*B cell markers +ve.
	*EBER +ve ~~-- diffuse~~.		*EBER diffusely +ve.

	==See also==		==See also==

Michael: /* See also */

2011-03-03T15:49:32Z

Michael: /* General */ tweak

2011-03-03T15:48:48Z

General: tweak

← Older revision		Revision as of 15:48, 3 March 2011
Line 4:		Line 4:
	*Rare.		*Rare.
	*B cell neoplasm associated with EBV.<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>		*B cell neoplasm associated with EBV.<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>
	**~~Develop~~ from a latent EBV infection ~~- which may be~~ detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/]. Accessed on: 3 March 2011.</ref>		**May develop from a clinically latent EBV infection that is detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/]. Accessed on: 3 March 2011.</ref>
	*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.		*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.

Michael: /* General */

2011-03-03T15:47:03Z

General

← Older revision		Revision as of 15:47, 3 March 2011
Line 4:		Line 4:
	*Rare.		*Rare.
	*B cell neoplasm associated with EBV.<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>		*B cell neoplasm associated with EBV.<ref>URL: [http://emedicine.medscape.com/article/431364-overview http://emedicine.medscape.com/article/431364-overview]. Accessed on: 10 February 2011.</ref><ref name=pmid15660500>{{cite journal \|author=Gottschalk S, Rooney CM, Heslop HE \|title=Post-transplant lymphoproliferative disorders \|journal=Annu. Rev. Med. \|volume=56 \|issue= \|pages=29–44 \|year=2005 \|pmid=15660500 \|doi=10.1146/annurev.med.56.082103.104727 \|url=}}</ref>
			**Develop from a latent EBV infection - which may be detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/]. Accessed on: 3 March 2011.</ref>
	*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.		*Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the [[liver]] prior to reaching the GI tract.

Michael: /* References */

2011-03-03T15:37:22Z

References

← Older revision		Revision as of 15:37, 3 March 2011
Line 23:		Line 23:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category:~~Lymphoma~~]].		[[Category:Haematopathology]]

← Older revision		Revision as of 17:37, 24 March 2017
Line 24:		Line 24:
	*[[Heart transplant pathology]].		*[[Heart transplant pathology]].
	*[[Lung transplant pathology]].		*[[Lung transplant pathology]].
			*[[Lymphoproliferative disorder]].

	==References==		==References==

← Older revision		Revision as of 15:49, 3 March 2011
Line 18:		Line 18:

	==See also==		==See also==
			*[[Diffuse large B cell lymphoma]] (DLBCL).
	*[[Heart transplant pathology]].		*[[Heart transplant pathology]].
	*[[Lung transplant pathology]].		*[[Lung transplant pathology]].